The European Committee for Medicinal Products for Human Use (CHMP) today announced its positive recommendation for the approval of Enbrel(R) (etanercept) as a treatment for children aged 8 years and ...

Eight months after bowing to FDA pressure to pull the original spot, Amgen has launched a revamped television ad for Enbrel (etanercept) that it says better explains the product’s psoriasis indication ...

Phase-III results for Eli Lilly’s experimental moderate-to-severe plaque psoriasis drug Ixekizumab hints at a possible brawl between the Indiana drugmaker and Amgen, if the FDA approves the drug.

ENBREL in the EU is approved for the following indications: Rheumatoid arthritis: ENBREL in combination with methotrexate is indicated for the treatment of moderate to severe active rheumatoid ...

THOUSAND OAKS, Calif. and COLLEGEVILLE, Pa., Feb. 4, 2011 /PRNewswire/ -- Amgen (Nasdaq: AMGN) and Pfizer Inc. (NYSE: PFE) today announced results from a new trial that demonstrated Enbrel® ...

THOUSAND OAKS, Calif., and COLLEGEVILLE, Pa., April 30, 2004 – Amgen (N), today announced that Enbrel® (etanercept) has been approved by the U.S. Food and Drug Ad ASDAQ: AMGN) and Wyeth ...

Amgen and Wyeth Pharmaceuticals, a division of Wyeth, today announced findings from a retrospective analysis, which demonstrated that ENBREL reduced C-reactive protein, a marker of inflammation, in ...

THOUSAND OAKS, Calif., Nov. 22, 2011 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today issued the following statement: Amgen today announced the issuance of U.S. Patent No. 8,063,182 related to Enbrel ® ...

Oct. 14, 2004 — The U.S. Food and Drug Administration (FDA) has approved caspofungin acetate for the empiric treatment of presumed fungal infections in the setting of febrile neutropenia, etanercept ...